Calcipotriol Targets LRP6 to Inhibit Wnt Signaling in Pancreatic Cancer

Michael D. Arensman1, Phillip Nguyen1, Kathleen M. Kershaw1, Anna R. Lay1, Claire A. Ostertag-Hill1, Mara H. Sherman2, Michael Downes2, Christopher Liddle3, Ronald M. Evans2,4, and David W. Dawson1,5

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy in need of more effective treatment approaches. One potential therapeutic target is Wnt/β-catenin signaling, which plays important roles in PDAC tumor initiation and progression. Among Wnt inhibitors with suitable in vivo biologic activity is vitamin D, which is known to antagonize Wnt/β-catenin signaling in colorectal cancer and have antitumor activity in PDAC. For this study, the relationship between vitamin D signaling, Wnt/β-catenin activity, and tumor cell growth in PDAC was investigated through the use of calcipotriol, a potent non-hypercalcemic vitamin D analogue. PDAC tumor cell growth inhibition by calcipotriol was positively correlated with vitamin D receptor expression and Wnt/β-catenin activity. Furthermore, vitamin D and Wnt signaling activity were found to be reciprocally linked through feedback regulation. Calcipotriol inhibited autocrine Wnt/β-catenin signaling in PDAC cell lines in parallel with decreased protein levels of the low-density lipoprotein receptor-related protein 6 (LRP6), a requisite coreceptor for ligand-dependent canonical Wnt signaling. Decrease in LRP6 protein seen with calcipotriol was mediated through a novel mechanism involving transcriptional upregulation of low-density lipoprotein receptor adaptor protein 1 (LDLRAP1). Finally, changes in LRP6 or LDLRAP1 expression directly altered Wnt reporter activity, supporting their roles as regulators of ligand-dependent Wnt/β-catenin signaling.

Implications: This study provides a novel biochemical target through which vitamin D signaling exerts inhibitory effects on Wnt/β-catenin signaling, as well as potential biomarkers for predicting and following tumor response to vitamin D–based therapy. Mol Cancer Res; 13(11); 1509–19. ©2015 AACR.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is a highly recalcitrant malignancy with an overall 5-year survival rate of 6% (1). Its poor prognosis is linked to its typically advanced clinical stage at diagnosis, rapid disease progression, and resistance to cytotoxic or targeted molecular therapies (2). Improved therapeutic approaches based on a detailed understanding of the molecular and cellular basis of PDAC are needed. One therapeutic target now under consideration is Wnt/β-catenin signaling, one of 12 core pathways and processes genetically altered in most PDAC (3).

Wnt signaling plays pivotal roles in embryogenesis and adult tissue homeostasis through its regulation of diverse biologic functions, including cell fate specification, proliferation, and cell migration. Wnt ligands are secreted glycoproteins that signal through Frizzled (FZD) receptor and low-density lipoprotein receptor-related protein 5 or 6 (LRP5 or LRP6) coreceptor. Activation of canonical Wnt signaling (hereafter referred to as Wnt/β-catenin–dependent signaling) culminates in the cytoplasmic accumulation of β-catenin and its translocation to the nucleus where it complexes with transcription factors and coactivators to drive context-dependent target gene expression (4). Deregulation of Wnt/β-catenin signaling occurs in many types of cancer either through key driver mutations or increased Wnt ligand–mediated receptor activation. In PDAC, Wnt/β-catenin signaling is required for tumor initiation (5) and confers traits associated with “stemness” in susceptible cell lines (6). Furthermore, Wnt/β-catenin signaling supports various protumorigenic phenotypes in established PDAC cell lines and has been correlated with aggressive clinical behavior in primary PDAC tumor samples (5, 7, 8).

Several Wnt inhibitors are now at various stages of preclinical and early clinical development (9). They include small-molecule inhibitors, blocking antibodies, inhibitory fusion proteins, peptide antagonists, and several naturally occurring compounds, including vitamin D. Calcitriol, the biologically active metabolite of vitamin D (and ligand of the vitamin D receptor), has been shown to disrupt Wnt/β-catenin signaling through multiple mechanisms. In colon cancer lines, calcitriol induces the vitamin D receptor (VDR) to directly bind β-catenin and increases E-cadherin expression to sequester β-catenin at adherens junctions, which leads to reduced β-catenin/TCF interaction and target gene expression (10). Calcitriol also indirectly increases the expression of DKK1, a secreted protein antagonist of Wnt/β-catenin signaling (11).
Vitamin D is acquired through dietary intake and ultraviolet light–mediated metabolism of its precursors in the skin. Vitamin D metabolites bind to VDR, a transcription factor that functions as an obligate heterodimer with the retinoid X receptor (RXR) to regulate the expression of target genes with vitamin D response elements. In addition to regulating calcium homeostasis, vitamin D exhibits anticancer action through a variety of antiproliferative, proapoptotic, and differentiation effects. Accordingly, vitamin D and its analogues are promising chemopreventative and chemotherapeutic agents for numerous malignancies. In relation to PDAC, some epidemiologic studies show higher intake or increased plasma levels of vitamin D correlate with decreased incidence of PDAC (12, 13). Although a published meta-analysis concludes no significant association between vitamin D levels and PDAC risk (14), a high prevalence of vitamin D insufficiency has been observed in patients with advanced pancreatic cancer (15). Published experimental studies show that vitamin D and its synthetic analogues inhibit the in vitro and in vivo growth of some but not all PDAC cell lines through proapoptotic and antiproliferative actions (16–18). A recent study by Sherman and colleagues finds that VDR also functions as a master transcriptional regulator of pancreatic stellate cell quiescence and that the vitamin D analogue calcipotriol can suppress pancreatitis and mediate stromal remodeling to improve chemotherapeutic drug delivery and survival in a Kras-driven mouse model of PDAC (19).

Here, we examine the potential interplay between Wnt/β-catenin and vitamin D signaling in PDAC. We show that the ability of calcipotriol to inhibit PDAC cell growth strongly correlates with decreased expression of Wnt signaling, which is correlated with and regulated by Wnt signaling. We demonstrate that calcipotriol induces expression of low-density lipoprotein receptor adaptor protein 1 (LRP6), which in turn mediates rapid reduction in LRP6 protein levels and corresponding inhibition of Wnt signaling, providing an additional novel mechanism by which vitamin D can inhibit Wnt signaling activity. Our findings suggest that, in addition to potential use as stromal therapy, vitamin D analogues are suitable agents for directly targeting tumor cells in the subset of pancreatic cancers and precursor lesions defined by Wnt-dependent growth activity and higher VDR expression.

Materials and Methods

Cell lines and reagents

All cell lines were cultured as previously described (8). AsPC-1, HPAF-2, MiaPaCa-2, and PANC-1 were purchased from the American Type Culture Collection in 2005. YAPC, Suit, and HCG25 were kindly provided by Dr. Eric Collisson (University of California, San Francisco) in 2012. Cell lines have not been further authenticated since initial receipt. Calcipotriol, Baflomycin A1, and CHIR99021 were purchased from Tocris.

Quantitative real-time PCR

RNA extraction, cDNA synthesis, and SYBR green qPCR were performed as previously described (8) using primers listed in Supplementary Table S1. All values were normalized to ACTB housekeeping gene.

Gene knockdown

AsPC-1 cells were transfected using Lipofectamine 2000 (Life Technologies) as per the manufacturer's instructions using 20 nmol/L of siRNAs purchased from GE Dharmacon, including control (D-001810-10-05), VDR (L-003448-00-0005), LDRAP1 (L-013025-00-0005), DKK1 (L-003843-01-0005), or combined 10 nmol/L of RXRA (L-003448-00-0005) and 10 nmol/L RXRB (L-003444-00-0005).

Western blot and immunoprecipitation

SDS-PAGE and immunoblots were performed as described (20) using antibodies for β-catenin (C2206; Sigma), tubulin (sc-5546; Santa Cruz Biotechnology), VDR (sc-13133), E-cadherin (sc-21791), DKK-1 (GTX62902; Genetex), LRP6 (CST3395; Cell Signaling Technology), RXRα (CST3085), RXRβ (CST8715), LDRAP1 (C20125; LSBio), or LC3B (ab48394; Abcam). For LRPI and LC3B immunoblots, lysates were resolved on 4% to 20% gradient gels. Coimmunoprecipitations were performed as described (21). Briefly, AsPC-1 lysates were precleared with A/G-PLUS agarose beads (Santa Cruz Biotechnology; sc-1008), or control isotype-matched IgG (Santa Cruz Biotechnology; sc-2025 or Abcam; ab46540). After multiple washes, immune complexes were boiled in 6× SDSPAGE loading dye, resolved by SDS-PAGE, and transferred to nitrocellulose membranes for immunoblotting.

Cell growth assays

MTT assays (ATCC) were carried out as per the manufacturer’s instructions in 96-well plates with initial plating of 500 (Suit2), 1,000 (Tu8988), or 2,000 (HPAF-2, YAPC, MiaPaCa-2, AsPC-1, and PANC-1) cells per well. Cells were allowed to adhere overnight and then treated with calcipotriol. Soft-agar assays were performed as previously described (20).

Wnt reporter assays

Baseline Wnt reporter activity was measured in dual luciferase assays (Promega) as previously described (8) by transient cotransfection with control plasmid with constitutive EF1α promoter driving Renilla expression (serving as a normalization control) and either BAR (beta-catenin–activated reporter, 12 TCF response elements driving luciferase expression) or fuBAR (found unresponsive BAR, contains mutated TCF response elements). In other experiments, Wnt reporter activity was measured in AsPC-1 stably transduced with both BAR reporter and Renilla control as previously described (20).

LRP6 overexpression

LRP6 or GFP (control) expression constructs in pCS2 vector have been previously described (22) and were kindly provided by Edward De Robertis (University of California, Los Angeles). Transfections were performed with X-tremeGENE9 (Roche) as per the manufacturer’s instructions.

RNA isolation, library generation, sequencing, and analysis

Total RNA was isolated from human pancreatic cancer cell lines as previously described (19). Sequencing libraries were prepared from 100 to 500 ng of total RNA using the TruSeq RNA sample preparation kit v2 (Illumina) according to the manufacturer’s protocol. Briefly, mRNA was purified, fragmented, and used for first- and second-strand cDNA synthesis followed by adenylation of 3’ ends. Samples were ligated to unique adapters and subjected to PCR amplification. Libraries were validated using the 2100 BioAnalyzer (Agilent), normalized, and pooled for sequencing.
RNA-seq libraries from three biologic replicates for each experimental condition were sequenced on the Illumina HiSeq 2000 using barcoded multiplexing and a 100-bp read length. Image analysis and base calling were performed with Illumina CASAVA 1.8.2. This yielded a median of 12.4 million usable reads per sample. Short read sequences were mapped to a UCSC hg19 reference sequence using the RNA-seq aligner STAR (23). Known splice junctions from hg19 were supplied to the aligner, and de novo junction discovery was also permitted. Differential gene expression analysis, statistical testing, and annotation were performed using Cuffdiff 2 (24). Transcript expression was calculated as gene-level relative abundance in fragments per kilobase of exon model per million mapped fragments and employed correction for transcript abundance bias (25). RNA-seq data are deposited in the National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA accession number SRP057571). Functional enrichment analysis was limited to gene ontology terms and examined using default parameters in the web-based Database for Annotation, Visualization and Integrated Discovery (DAVID, v6.7; http://david.abcc.ncifcrf.gov; ref. 26).

**Microarray data analysis**

Gene set enrichment analysis (GSEA) method (http://www.broadinstitute.org/gsea; ref. 27) was used to determine whether a defined pancreatic-specific Wnt/β-catenin target gene set showed statistically significant concordance with VDR expression in a previously published gene expression microarray dataset of 25 primary human PDAC samples (deposited in NCBI GEO under accession number GSE32688). GSEA default parameter settings and the Pearson metric for ranking genes were used with VDR expression serving as a continuous phenotypic variable. The defined pancreatic-specific Wnt/β-catenin target gene set was the previously published (20) overlap of downregulated transcripts observed in AsPC-1 in response to either Wnt inhibitor ICG-001 or CTNNB1 siRNA transfection.

**Statistical methods**

Statistical analyses were performed in GraphPad Prism (ver 5.04). Student r tests were used to compare continuous variables. The level of significance for all statistical tests was defined as α = 0.05.

**Results**

**PDAC growth inhibition by calcipotriol is linked to VDR expression and Wnt signaling**

In previous work, we described a distinct subset of PDAC cell lines with higher levels of autocrine Wnt/β-catenin signaling and an anchorage-independent growth phenotype responsive to genetic or pharmacologic inhibition of Wnt (8). Given that vitamin D inhibits Wnt signaling in colon cancer (10, 11), we hypothesized that the growth-inhibitory effects of the vitamin D on PDAC tumor cells might depend on their baseline autocrine Wnt/β-catenin signaling activity. Autocrine Wnt/β-catenin activity was measured across a panel of PDAC cell lines by dual luciferase reporter assays to determine the ratio of BAR (β-catenin–activated reporter, 12 TCF response elements driving luciferase expression) to fuBAR (found unresponsive BAR, contains mutated TCF response elements; ref. 28). AsPC1, HPAF-2, YAPC, and Suit2 each had higher levels of autocrine Wnt activity (hereafter designated as high-BAR lines), whereas MiaPaCa-2, PANC-1, and HCG25 each had lower or absent levels of autocrine Wnt activity (hereafter designated as low-BAR lines; Fig. 1A).

Levels of autocrine Wnt activity were observed to closely parallel VDR protein expression (Fig. 1A) with Western blots showing higher VDR expression (high-VDR) in high-BAR lines and low or undetectable VDR expression (low-VDR) in low-BAR lines. Furthermore, calcipotriol inhibited anchorage-dependent growth of high-BAR/high-VDR cell lines in a dose-dependent manner at concentrations ranging from 10 nmol/L to 1 μmol/L but was unable to inhibit the growth of low-BAR/low-VDR cell lines even at concentrations up to 10 μmol/L (Fig. 1B). Calcipotriol inhibited anchorage-independent growth of high-BAR/high-VDR cell lines in soft-agar assays (Fig. 1C), a phenotype we previously showed to be dependent on Wnt signaling in high-BAR PDAC lines (8). These results demonstrate that PDAC growth inhibition by calcipotriol correlates with VDR expression status and might be functionally linked to underlying differences in Wnt activity, whereby Wnt/β-catenin signaling serves as a mediator and/or target of vitamin D action.

To more directly address mechanistic links between vitamin D and Wnt signaling in PDAC, AsPC-1 cells stably transduced with BAR were treated with increasing concentrations of calcipotriol. Calcipotriol significantly inhibited Wnt/β-catenin activity in a dose-dependent manner as measured by BAR reporter (Fig. 2A). Calcipotriol also significantly inhibited expression of the endogenous Wnt/β-catenin transcriptional target AXIN2 across all high-BAR/high-VDR cell lines (Fig. 2B). To confirm that calcipotriol inhibited Wnt signaling in a VDR-dependent manner, cells were treated in the context of siRNA-mediated VDR knockdown. VDR knockdown fully rescued inhibition of BAR reporter seen with calcipotriol (Fig. 2C and D), indicating that Wnt inhibition by calcipotriol was VDR-dependent and did not occur through off-target or other receptor-independent effects.

We next explored the mechanism by which calcipotriol inhibits Wnt activity in PDAC. In colon cancer cell lines, ligand-activated VDR has been shown to directly interact with β-catenin, leading to cytoplasmic sequestration of β-catenin and inhibition of β-catenin/TCF-mediated transcription (10). Addressing this possibility in PDAC, cell extracts of AsPC-1 treated with either vehicle or calcipotriol were immunoprecipitated with anti-β-catenin antibody. Although E-cadherin coimmunoprecipitated with β-catenin as expected, VDR failed to coimmunoprecipitate with β-catenin either in the presence or absence of calcipotriol (Supplementary Fig. S1A). Reverse coimmunoprecipitation with anti-VDR antibody also failed to demonstrate an interaction between VDR and β-catenin (data not shown), suggesting Wnt inhibition by calcipotriol does not occur through sequestration of β-catenin by ligand-activated VDR. Calcitriol has been shown to increase expression of the secreted Wnt inhibitor DKK1 through an indirect transcriptional mechanism (11). Although calcipotriol increased DKK1 protein levels in AsPC-1, this increase was functionally decoupled from inhibition of Wnt signaling by calcipotriol, as inhibition of BAR activity by calcipotriol was not rescued by concurrent siRNA-mediated knockdown of DKK1 (Supplementary Fig. S1B and S1C). Furthermore, siRNA knockdown of DKK1 paradoxically reduced BAR activity in the absence of calcipotriol, indicating DKK1 does not functionally inhibit Wnt signaling in AsPC-1 cells. Together, these results suggest that calcipotriol inhibits Wnt signaling in PDAC through an alternative mechanism.
Calcipotriol reduces LRP6 protein levels

LRP6 is a requisite coreceptor for Wnt ligand–initiated canonical signaling. We noted that LRP6 protein levels decreased within 6 hours of calcipotriol treatment in all high-BAR/high-VDR PDAC lines (Fig. 3A and B), but not in low-BAR/low-VDR PDAC lines (Supplementary Fig. S2A). Knockdown of VDR by siRNA blocked the decrease in LRP6 protein observed with calcipotriol (Fig. 2C), indicating that the decrease in LRP6 protein by calcipotriol is VDR-dependent. Transient overexpression of wild-type LRP6 increased BAR activity compared with GFP control vector in both vehicle- and calcipotriol-treated cells (Fig. 3C), indicating changes in LRP6 expression directly alter Wnt reporter activity in AsPC-1.

When normalized to vehicle control, calcipotriol inhibited BAR activity in control GFP- or LRP6-transfected cells to a similar extent (31% and 28% relative change, respectively; Fig. 3C), suggesting calcipotriol may inhibit BAR activity through an LRP6-independent mechanism. Alternatively, overexpressed LRP6 might remain subject to relative downregulation by calcipotriol via the mechanism further detailed below.

To discriminate between genomic versus potential nongenomic mechanisms of action of VDR on LRP6 levels, the VDR transcriptional coactivators RXRa and RXRb were knocked down in tandem by siRNA transfection. Combined RXRa/RXRb knockdown blocked the decrease in LRP6 seen with calcipotriol, arguing again in favor of a VDR/RXR-dependent transcriptional mechanism (Fig. 3D). However, although calcipotriol decreased LRP6 protein levels as early as 6 hours in each of the high-BAR/high-VDR PDAC lines, LRP6 transcript levels only differed between calcipotriol and vehicle control treatments after 24 hours in AsPC-1, HPAF-2, and YAPC (Fig. 3E and F) and not at all in Suit2 (Fig. 3F). This difference in transcript levels at 24 hours specifically reflected an increase in LRP6 expression in vehicle-treated cells that did not occur in calcipotriol-treated cells. Given LRP6 protein decreases prior to any effect on LRP6 transcript levels, we speculated that calcipotriol inhibits Wnt signaling in PDAC by regulating LRP6 protein levels indirectly through an VDR/RXR-dependent transcriptional mechanism.
**Figure 2.**
Calcipotriol mediates inhibition of Wnt signaling through VDR. A, dose-response curve for calcipotriol on Wnt signaling as measured at 24 hours in AsPC-1 cells with stable BAR-luciferase reporter. B, AXIN2 expression measured by qPCR at 24 hours following treatment with vehicle or 100 nmol/L (AsPC-1), 5 μmol/L (YAPC), or 1 μmol/L (HPAF-2 and Suit2) calcipotriol. C, VDR, LRP6, and tubulin (loading control) Western blots and (D) BAR-luciferase activity for AsPC-1 transfected with either control or VDR siRNA for 48 hours and an additional 24-hour treatment with vehicle or 100 nmol/L calcipotriol. All values were normalized to respective controls, with BAR reported as mean ± SD and qPCR reported as mean ± SEM. One representative experiment from at least three biologic repeats is shown. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

**LDLRAP1 mediates reduced LRP6 protein levels in response to calcipotriol**

To further explore the manner in which LRP6 protein was decreased in response to calcipotriol, RNA sequencing (RNA-seq) was performed on AsPC-1 cells. Comparison of transcriptomes following calcipotriol treatment confirmed expression of known vitamin D transcriptional targets, including CYP24A1, as the most highly upregulated gene (Fig. 4A and Supplementary Table S2). A total of 325 genes (220 upregulated and 105 downregulated) was signiﬁcantly upregulated at 2 and 6 hours after calcipotriol treatment (Fig. 4A). LDLRAP1 was signiﬁcantly upregulated at 2 and 6 hours after calcipotriol treatment (Fig. 4A). LDLRAP1 expression to changes in LRP6 protein and Wnt signaling, siRNA-mediated knockdown of LDLRAP1 signiﬁcantly abrogated the reduction in LRP6 protein seen with calcipotriol treatment (Fig. 4D). Concurrent evaluation of Wnt reporter showed that LDLRAP1 knockdown mildly increased baseline BAR activity in the vehicle control with partial reversal of the inhibition of BAR activity seen with calcipotriol treatment (Fig. 4E). Although the
relative reduction in BAR activity observed with calcipotriol treatment in control versus LDLRAP1 siRNA-transfected cells was similar (30% and 31%, respectively), changes in the absolute level of BAR activity (Fig. 4E) paralleled the observed changes in LRP6 expression (Fig. 4D), potentially implicating a link between regulation of LRP6 expression and Wnt reporter activity by calcipotriol through LDLRAP1. In summary, LDLRAP1 is a direct transcriptional target of ligand-activated VDR that mediates reduction in LRP6 protein in coordination with the inhibition of Wnt signaling observed with calcipotriol.

VDR is regulated by Wnt signaling

Extending upon the observed correlation between VDR expression and autocrine Wnt signaling activity across a panel of PDAC cell lines (Fig. 1A), we determined whether a similar correlation exists in clinical specimens. GSEA of a previously published cohort of 25 primary PDAC tumors (38) confirmed positive enrichment of a PDAC-specific Wnt/β-catenin target gene set in tumors with higher VDR expression (Fig. 5A, normalized enrichment score = 1.39, false discovery rate q value = 0.08). To determine whether VDR is directly regulated by Wnt/β-catenin signaling in PDAC, AsPC-1 cells with stable BAR reporter were transfected with siRNA against WNT7B, a Wnt ligand previously shown to be essential for autocrine Wnt signaling activity in this cell line (8). WNT7B knockdown significantly inhibited BAR activity with a concomitant ~70% decrease in VDR expression (Fig. 5B). Addressing reciprocal activation of Wnt/β-catenin signaling, high-BAR/high-VDR and low-BAR/low-VDR

---

**Figure 3.**
Calcipotriol treatment reduces LRP6 expression in PDAC. A and B, Western blots for LRP6 or tubulin (loading control) were performed on whole-cell lysates at indicated time points after cell line treatment with vehicle or 100 nmol/L (AsPC-1), 5 μmol/L (YAPC), or 1 μmol/L (HPAF-2 and Suit2) calcipotriol. C, BAR-luciferase activity for AsPC-1 transfected with full-length LRP6 expression vector or control GFP vector for 48 hours and measured after a further 24-hour treatment with vehicle or 100 nmol/L calcipotriol. D, RXRα, RXRβ, LRP6, and tubulin Western blots on AsPC-1 whole-cell lysates after control or tandem RXRA and RXRB siRNA transfection for 48 hours and further treatment with vehicle or 100 nmol/L calcipotriol for 24 hours. E and F, LRP6 gene expression measured by qPCR after 100 nmol/L calcipotriol treatment for indicated times. Cells were synchronized by serum starvation prior to calcipotriol treatment. All values were normalized to respective controls, with BAR reported as mean ± SD and qPCR reported as mean ± SEM. One representative experiment of 2 to 3 biologic repeats is shown. *, P < 0.05; ***, P < 0.001; ns, not significant.
Calcipotriol activates LDLRAP1 to regulate LRP6 protein levels. A, a heat map of selected genes from RNA-seq after 2 or 6 hours of treatment with vehicle or 100 nmol/L calcipotriol. B, a Western blot for LC3B, LRP6, and tubulin (loading control) after AsPC-1 cells were treated with vehicle, 100 nmol/L calcipotriol, 100 nmol/L bafilomycin A1, or a combination of the two for 6 hours. C, LDLRAP1 expression by qPCR after treatments described in Fig. 3E. D, Western blot for LDLRAP1, LRP6, and tubulin (loading control). AsPC-1 cells were transfected with control or LDLRAP1 siRNA for 48 hours and then treated with vehicle or 100 nmol/L calcipotriol for 24 hours. Relative densitometry values for LDLRAP1 and LRP6 expression normalized to tubulin loading control are shown beneath the corresponding blots. E, starvation luciferase activity in AsPC-1 cells treated as in D. Values are shown normalized to respective controls, with BAR reported as mean ± SEM. One representative experiment of 3 biological repeats is shown.

**Discussion**

Diverse antitumorigenic actions of vitamin D have been shown in vitro and in vivo preclinical studies of pancreatic cancer (16–19). In particular, nonhypercalcemic analogues of vitamin D circumventing dose-limiting side effects of hypercalcemia and hypercalciuria represent especially promising chemotherapeutic agents for PDAC and other malignancies. To date, there are only limited published data addressing the clinical efficacy of vitamin D in PDAC. In a nonrandomized phase II clinical trial of advanced stage, PDAC single-agent vitamin D analogue seocalcitol (EB1089) was well tolerated but did not improve patient survival (40). This study involved patients with advanced disease and did not address biomarkers such as VDR expression levels, Wnt signaling activity, or other biochemical changes to determine their potential roles in predicting biologic response to seocalcitol.

Another phase II trial of advanced PDAC involving oral vitamin D (calcitriol) in combination with docetaxel demonstrated prolonged time to disease progression relative to docetaxel alone (41). Offering a potential explanation, VDR was recently shown to function as a stromal targeting agent capable of enhancing delivery of gemcitabine chemotherapy in a genetically engineered mouse model of PDAC (19). Clinical trials focused on this exciting result are now underway utilizing the vitamin D analogue paricalcitol (i.e., NCT#02030860). Importantly, newer synthetic agents for PDAC and other malignancies. To date, there are only limited published data addressing the clinical efficacy of vitamin D in PDAC. In a nonrandomized phase II clinical trial of advanced stage, PDAC single-agent vitamin D analogue seocalcitol (EB1089) was well tolerated but did not improve patient survival (40). This study involved patients with advanced disease and did not address biomarkers such as VDR expression levels, Wnt signaling activity, or other biochemical changes to determine their potential roles in predicting biologic response to seocalcitol.

Another phase II trial of advanced PDAC involving oral vitamin D (calcitriol) in combination with docetaxel demonstrated prolonged time to disease progression relative to docetaxel alone (41). Offering a potential explanation, VDR was recently shown to function as a stromal targeting agent capable of enhancing delivery of gemcitabine chemotherapy in a genetically engineered mouse model of PDAC (19). Clinical trials focused on this exciting result are now underway utilizing the vitamin D analogue paricalcitol (i.e., NCT#02030860). Importantly, newer synthetic
vitamin D analogues (i.e., calcipotriol and paricalcitol) may be more efficacious as they are resistant to degradation by the product of the VDR target gene CYP24A1, which is rapidly induced by liganded VDR and is responsible for rapid feedback inhibition of naturally occurring vitamin D (i.e., calcitriol). Although tumor stroma is an important target for evaluating the effects of vitamin D–based therapy in PDAC, such stromal effects also need to be cautiously interpreted in relation to any further direct actions of vitamin D on PDAC tumor cells themselves. For instance, calcitriol directly potentiates the cytotoxic activity of gemcitabine in PDAC cell lines both in vitro and in vivo (17). Furthermore, our results here demonstrate functional cross-talk between VDR and Wnt/β-catenin signaling in PDAC tumor cells that may have significant bearing on the clinical and biologic response of subsets of PDAC tumors (i.e., those with higher autocrine Wnt signaling) to vitamin D analogues. Pancreatic stromal cells are also influenced by paracrine Wnt signaling (42), offering a viable signaling pathway through which vitamin D could exert its antistromal effects.

Our calcitriol results are in line with previous studies showing that vitamin D and its analogues inhibit the growth of certain PDAC cell lines (i.e., AsPC-1) but not others (i.e., MiaPaCa-2 and PANC-1; ref. 18). Our study expands this observation to additional PDAC cell lines and indicates that growth-inhibitory activity is dependent on levels of VDR expression, which in turn is positively regulated by Wnt/β-catenin signaling. This bidirectional relationship between Wnt and vitamin D signaling could have significant bearing on identifying patients most likely to respond to vitamin D–based therapy and raises a potential confounding issue related to the use of vitamin D analogues either alone or in combination with other therapeutic Wnt inhibitors. Namely, inhibition of Wnt may reduce Wnt/β-catenin–regulated expression of VDR message, with the potential to blunt any further VDR-dependent vitamin D response. Although other mechanisms (i.e.,

Figure 5. VDR is regulated by Wnt signaling in PDAC. A, GSEA (27) enrichment plot for PDAC-specific Wnt/β-catenin target gene set determined relative to VDR expression phenotype using a published gene expression microarray dataset of 25 primary PDAC tumor samples. The top curve shows a running enrichment score for the target gene set, whereas the middle portion shows a heatmap of VDR expression (red, high; blue, low) and bottom portion shows the value of the ranking metric down the list of genes. B, BAR-luciferase activity and VDR expression by qPCR 48 hours after transfection of AsPC-1 cells with control or WNT7B siRNA. C, BAR-luciferase activity and VDR expression by qPCR 24 hours after treatment of indicated PDAC cell lines with vehicle or 5 μmol/L CHIR99021 (CHIR). Values shown are normalized to respective controls, with BAR reported as mean ± SD and qPCR reported as mean ± SEM. One representative experiment of 3 biologic repeats is shown. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Calcipotriol inhibited anchorage-independent growth in cell lines with high endogenous Wnt activity, a phenotype we previously showed to be decoupled from vitamin D extending beyond its actions as an inhibitor of Wnt signaling in these cell lines (8). These divergent results are not surprisingly given known pleiotropic antitumor effects attributed to vitamin D extending beyond its actions as an inhibitor of Wnt signaling. Vitamin D–mediated growth-inhibitory effects in PDAC have previously been attributed to cell-cycle arrest occurring via upregulation of key regulators of cell cycle such as p21 and p27 (16, 18). Indeed, our RNA-seq analysis of calcipotriol-treated AsPC-1 cells revealed altered expression of several key mediators of cell cycle (i.e., SKP2 and CDKN1A) as well as apoptosis (i.e., BIRC5 and BCL10).

Calcipotriol specifically inhibited Wnt/β-catenin transcriptional activity in PDAC cell lines characterized by higher levels of Wnt ligand–mediated autocrine signaling and VDR expression. Vitamin D was previously shown to inhibit Wnt/β-catenin signaling in colon cancer cell lines by mediating an interaction between VDR and β-catenin that disrupts β-catenin/TCP-mediated transcription (10) and by indirectly increasing expression of the secreted Wnt antagonist DKK1 (11). We were unable to detect a physical interaction between VDR and β-catenin in PDAC lines either in the presence or absence of calcipotriol. While calcipotriol did induce the expression of DKK1 in AsPC-1 cells, this could not be functionally linked to its inhibition of Wnt signaling, as DKK1 knockdown did not rescue the inhibition of Wnt signaling seen with calcipotriol. Nevertheless, our results do not exclude other proposed mechanisms of VDR and β-catenin cross-regulation, such as possible re-distribution of β-catenin across the genome in response to calcipotriol treatment (43, 44).

This study provides a novel mechanism through which vitamin D could negatively regulate Wnt signaling. Protein levels of the Wnt coreceptor LRP6 were reduced as early as 6 hours after calcipotriol treatment. This reduction was dependent upon VDR transcriptional activity because knockdown of the VDR cotranscriptional activator RXR rescued the reduction of LRP6 protein seen with calcipotriol treatment. Rapid reduction of LRP6 protein was not the result of reduced LRP6 transcript levels, which were only altered 24 hours after calcipotriol treatment when LRP6 transcript levels actually increased in vehicle control and not in calcipotriol-treated cells. We speculate that the dramatic increase in LRP6 transcript seen at 24 hours in control cells may be tied to cell-cycle–dependent changes in LRP6 expression (45, 46), whereas calcipotriol-treated cells under cell-cycle arrest would be expected to retain lower levels of LRP6 transcript.

LRP6 is a critical mediator of ligand-mediated Wnt/β-catenin signaling. Although we show overexpression of LRP6 increased Wnt reporter activity in the absence or presence of calcipotriol (Fig. 3C), this cannot be concluded to represent specific rescue of the mechanism by which calcipotriol directly inhibits the pathway. RNA-seq analysis presented here offers several additional potential regulators of Wnt signaling that could mediate calcipotriol effects, including BAMBI (BMP and activin membrane bound inhibitor) that was significantly decreased within 2 hours of calcipotriol treatment. BAMBI is a known Wnt/β-catenin agonist that promotes the interaction between Fzd and Dvl (47). We are now investigating BAMBI and other alternative targets through which vitamin D may directly inhibit Wnt signaling in pancreatic cancer.

This study also further focused on induction of LDLRAP1 message and protein by calcipotriol and the role of LDLRAP1 in regulating LRP6 protein levels. LDLRAP1 is an adapter protein that binds to tyrosine motifs in the cytoplasmic tail of LDL receptors, which couples them to the endocytic machinery of the clathrin-coated pit (31). LDLRAP1 promotes clathrin-mediated endocytosis of LDLR and LRP2 (29–31). Tyrosine motifs in the cytoplasmic tail of LDL receptor family member LRP6 are critical for its clathrin-mediated internalization (49). Our data establish an additional role for LDLRAP1 in regulating steady-state levels of LRP6 and lead us to speculate that LDLRAP1 facilitates endocytosis and lysosome-mediated degradation of LRP6.

In summary, we have elucidated a bidirectional feedback interaction between Wnt and vitamin D signaling in PDAC. Upon activation, Wnt signaling induces expression of VDR. Furthermore, ligand-activated VDR positively regulates the transcription of LDLRAP1. LDLRAP1 contributes to a rapid reduction in proteins levels of LRP6, a critical coreceptor for ligand-dependent Wnt signaling. Activation of Wnt signaling induces the expression of VDR in PDAC tumor cells, which renders those cells susceptible to vitamin D antitumor effects. In addressing the reciprocal relationship between vitamin D and Wnt signaling, this study offers new insights into the possible use of vitamin D as a therapeutic Wnt inhibitor, as well as possible biomarkers for predicting or following response to calcipotriol and other vitamin D analogues.

Disclosure of Potential Conflicts of Interest
R.M. Evans has ownership interest (including patents) in XTuit Pharmaceuticals, Inc. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Conception and design: M.D. Arensman, K.M. Kershaw, M. Downes, D.W. Dawson
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): M.D. Arensman, P. Nguyen, K.M. Kershaw, A.R. Lay, C.A. Ostertag-Hill, M.H. Sherman, D.W. Dawson
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M.D. Arensman, P. Nguyen, K.M. Kershaw, A.R. Lay, M.H. Sherman, C. Liddle, D.W. Dawson
Writing, review, and/or revision of the manuscript: M.D. Arensman, P. Nguyen, M.H. Sherman, M. Downes, R.M. Evans, D.W. Dawson
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M.D. Arensman, A.R. Lay, D.W. Dawson
Study supervision: M.D. Arensman, M. Downes, D.W. Dawson

Grant Support
M.D. Arensman was supported by U54CA051037-01A1 from the National Cancer Institute (NCI) and U54CA119338 from the National Institute of General Medical Sciences (NIGMS). D.W. Dawson was supported by a grant from the NIH (K22CA151721) and the American Cancer Society (RSG-12-083-01-BCR).
References


Molecular Cancer Research

Calcipotriol Targets LRP6 to Inhibit Wnt Signaling in Pancreatic Cancer


Updated version

Access the most recent version of this article at:
doi:10.1158/1541-7786.MCR-15-0204

Supplementary Material

Access the most recent supplemental material at:
http://mcr.aacrjournals.org/content/suppl/2015/08/08/1541-7786.MCR-15-0204.DC1

Cited articles

This article cites 48 articles, 22 of which you can access for free at:
http://mcr.aacrjournals.org/content/13/11/1509.full.html#ref-list-1

Citing articles

This article has been cited by 4 HighWire-hosted articles. Access the articles at:
/content/13/11/1509.full.html#related-urls

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.